{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:23:04Z","timestamp":1791321784809,"version":"4.3.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,7,23]],"date-time":"2016-07-23T00:00:00Z","timestamp":1469232000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s12026-016-8843-5","type":"journal-article","created":{"date-parts":[[2016,7,23]],"date-time":"2016-07-23T07:38:35Z","timestamp":1469259515000},"page":"419-422","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study"],"prefix":"10.1007","volume":"65","author":[{"given":"Maurizio","family":"Benucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Li","family":"Gobbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bandinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Damiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Infantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Fusaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Batticciotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piercarlo","family":"Sarzi-Puttini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Atzeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Meacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,23]]},"reference":[{"key":"8843_CR1","unstructured":"WHO, World Health Organization. Expert Committee on Biological Standardization. Geneva, 19 to 23 October 2009. Guidelines on evaluation of similar biotherapeutic products (SBPs). 2009. http:\/\/www.who.int\/biologicals\/areas\/biological_therapeutics\/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf . Accessed 19 Feb 2015."},{"key":"8843_CR2","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on Similar Biological Medicine Products (CHMP\/437\/04 Rev 1). 23 October 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/10\/WC500176768.pdf . Accessed 2 Jul 2015."},{"key":"8843_CR3","unstructured":"U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER). Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Guidance for Industry. April 2015. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM291128.pdf . Accessed 2 Jul 2015."},{"key":"8843_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.biologicals.2014.05.005","volume":"42","author":"BG Feagan","year":"2014","unstructured":"Feagan BG, Choquette D, Ghosh S, et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals. 2014;42:177\u201383.","journal-title":"Biologicals"},{"key":"8843_CR5","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.4161\/mabs.32221","volume":"6","author":"SK Jung","year":"2014","unstructured":"Jung SK, Lee KH, Jeon JW, et al. Physicochemical characterization of Remsima. mAbs. 2014;6:1163\u201377.","journal-title":"mAbs"},{"key":"8843_CR6","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","volume":"72","author":"W Park","year":"2013","unstructured":"Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72:1605\u201312.","journal-title":"Ann Rheum Dis"},{"key":"8843_CR7","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/nbt.2438","volume":"30","author":"HC Ebbers","year":"2012","unstructured":"Ebbers HC, Crow SA, Vulto AG, et al. Interchangeability, immunogenicity and biosimilars. Nat Biotechnol. 2012;30:1186\u201390.","journal-title":"Nat Biotechnol"},{"issue":"Suppl. 1","key":"8843_CR8","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1007\/s10198-014-0589-1","volume":"15","author":"L T\u00f3thfalusi","year":"2014","unstructured":"T\u00f3thfalusi L, Endr\u00e9nyi L, Chow SC. Statistical and regulatory considerations in assessments of interchangeability of biological drug products. Eur J Health Econ. 2014;15(Suppl. 1):S5\u201311.","journal-title":"Eur J Health Econ"},{"key":"8843_CR9","unstructured":"AIFA: Position paper. I farmaci biosimilari. 13\/05\/2013."},{"issue":"1","key":"8843_CR10","first-page":"1","volume":"33","author":"F Atzeni","year":"2015","unstructured":"Atzeni F, Sebastiani M, Ricci C, Celano A, Gremese E, Iannone F, et al. Position paper of Italian rheumatologists on the use of biosimilar drugs. Clin Exp Rheumatol. 2015;33(1):1\u20134.","journal-title":"Clin Exp Rheumatol"},{"key":"8843_CR11","doi-asserted-by":"publisher","unstructured":"Park W, Yoo DH, Miranda P, Brzosko M, Wiland P, Gutierrez-Ure\u00f1a S, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2016. doi: 10.1136\/annrheumdis-2015-208783 .","DOI":"10.1136\/annrheumdis-2015-208783"},{"key":"8843_CR12","doi-asserted-by":"publisher","unstructured":"Meacci F, Manfredi M, Infantino M, Grossi V, Benucci M. Infliximab and CT-P13 immunogenicity assessment in PLANETAS and PLANETRAS main and extension studies: utility of laboratory methods description. Ann Rheum Dis. 2016. doi: 10.1136\/annrheumdis-2016-210078 .","DOI":"10.1136\/annrheumdis-2016-210078"},{"key":"8843_CR13","doi-asserted-by":"crossref","unstructured":"Ruiz-Arg\u00fcello MB, Maguregui A, Ruiz Del Agua A, Pascual-Salcedo D, Mart\u00ednez-Feito A, Jurado T, et al. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars. Ann Rheum Dis. 2016","DOI":"10.1136\/annrheumdis-2015-208684"},{"issue":"4","key":"8843_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.biologicals.2016.03.006","volume":"44","author":"J Braun","year":"2016","unstructured":"Braun J, Kudrin A. Switching to biosimilar infliximab (CT-P13): evidence of clinical safety, effectiveness and impact on public health. Biologicals. 2016;44(4):257\u201366. doi: 10.1016\/j.biologicals.2016.03.006 .","journal-title":"Biologicals"},{"issue":"12","key":"8843_CR15","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1111\/jgh.12997","volume":"30","author":"YS Jung","year":"2015","unstructured":"Jung YS, Park DI, Kim YH, Lee JH, Seo PJ, Cheon JH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2015;30(12):1705\u201312. doi: 10.1111\/jgh.12997 .","journal-title":"J Gastroenterol Hepatol"},{"issue":"Suppl. 1","key":"8843_CR16","first-page":"35e44","volume":"9","author":"SH Park","year":"2015","unstructured":"Park SH, Kim YH, Lee JH, Kwon HJ, Lee SH, Park DI, et al. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol. 2015;9(Suppl. 1):35e44.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"8843_CR17","first-page":"6","volume":"60","author":"YS Kang","year":"2015","unstructured":"Kang YS, Moon HH, Lee SE, Lim YJ, Kang HW. Clinical experience of the use of CT-P13, a Biosimilar to Infliximab in patients with inflammatory Bowel disease: a case series. Dig Dis Sci. 2015;60:6.","journal-title":"Dig Dis Sci"},{"key":"8843_CR18","doi-asserted-by":"publisher","unstructured":"Sieczkowska J, Jarze\u02dbbicka D, Banaszkiewicz A, Plocek A, Gawronska A, Toporowska-Kowalska A, et al. Switching between infliximab originator and biosimilar in pediatric patients with inflammatory bowel disease. Preliminary observation. J Crohns Colitis. 2016;10(2):127\u201332. doi: 10.1093\/ecco-jcc\/jjv233 .","DOI":"10.1093\/ecco-jcc\/jjv233"},{"key":"8843_CR19","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1517\/14712598.2015.1103733","volume":"15","author":"E Nikiphorou","year":"2015","unstructured":"Nikiphorou E, Kautiainen H, Hannonen P, Asikainen J, Kokko A, Rannio T, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677\u201383.","journal-title":"Expert Opin Biol Ther"},{"key":"8843_CR20","doi-asserted-by":"publisher","unstructured":"Gentileschi S, Barreca C, Bellisai F, Biasi G, Brizi MG, de Stefano R, et al. Switch from Infliximab to Infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases. Expert Opin Biol Ther. 2016. doi: 10.1080\/14712598.2016.1198765 .","DOI":"10.1080\/14712598.2016.1198765"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-016-8843-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12026-016-8843-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-016-8843-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-016-8843-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T16:56:17Z","timestamp":1568220977000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12026-016-8843-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,23]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["8843"],"URL":"https:\/\/doi.org\/10.1007\/s12026-016-8843-5","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,23]]}}}